FDA Approves FAVLYXA — Avyxa Pharma, LLC

# FDA Approves Avyxa Pharma's FAVLYXA (Fluorouracil) for Intravenous Use The FDA has approved Avyxa Pharma's FAVLYXA (fluorouracil) for intravenous administration, marking the company's entry into the oncology market and positioning it to compete in the mature but essential chemotherapy segment. The approval of this generic formulation could increase price competition in the fluorouracil market while expanding Avyxa's portfolio in cancer care therapeutics.